Biomarker Deep Dive: Omega-3 (EPA+DHA)

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the “active” long-chain omega-3s—most strongly linked to cardiometabolic outcomes, triglycerides, brain/eye biology, and inflammatory signaling. Unlike ALA (the plant omega-3), your body converts ALA → EPA/DHA inefficiently, so improving status usually requires fatty fish or direct EPA/DHA supplementation. 

This deep dive gives you a practical, scan-first framework to interpret results and act.

TL;DR: What your EPA + DHA result usually means

If EPA+DHA is low

• This typically reflects low omega-3 intake (little fatty fish, no algae/fish oil).

• Focus on a food-first plan + consistent retesting (same method).

• If you’re using omega-3 for triglycerides or a specific clinical goal, dosing should be clinician-guided.

If EPA+DHA is borderline

• Often fixable with 2–3 fatty fish meals/week or modest supplementation.

• “Borderline” is where consistency matters most: omega-3 status is a habit biomarker.

If EPA+DHA is high

• Often due to regular fatty fish intake or supplements.

• High-dose omega-3 has trade-offs in some populations (see atrial fibrillation section below). 

What Omega-3 EPA + DHA are

EPA and DHA are long-chain polyunsaturated fats found primarily in:

• fatty fish and seafood (salmon, sardines, herring, mackerel)

• algae oil (vegetarian source, often DHA-forward)

They are incorporated into cell membranes, including red blood cells (RBCs), influencing membrane fluidity and downstream signaling.

Why EPA + DHA matter (the “so what”)

Omega-3 EPA/DHA status is most often discussed for:

1. Triglycerides: high-dose prescription omega-3 (4 g/day) can substantially lower triglycerides under medical supervision. 

2. Cardiovascular diet pattern: multiple heart-health orgs emphasize eating fish twice per week as a dietary foundation. 

3. Pregnancy & lactation: some European guidance highlights DHA intake targets for pregnancy/lactation (see decision section). 

Interpretation: a decision-tree that actually helps

Step 1 — Identify what test you have

Common formats:

A) Omega-3 Index (RBC EPA + DHA %)

• Measures EPA+DHA as a percentage of total fatty acids in RBC membranes.

• Often used as a longer-term status marker (weeks–months). 

B) Plasma/serum EPA + DHA

• More sensitive to recent meals/supplements and short-term changes.

Rule: Do not compare across methods. Trend within the same lab/method.

Step 2 — Interpret by zones (relative to your lab reference)

Because reference ranges differ, use relative zones plus your context:

Zone A:  Below range / clearly low

Likely insufficient intake. Action is straightforward: food-first omega-3 plan, then retest.

Zone B: Borderline / low-normal

This is common and usually responds to consistent dietary changes. If you’re targeting triglycerides or inflammatory conditions, confirm with your clinician what dose/form is appropriate.

Zone C:  High

Often reflects supplements. High intake isn’t automatically “better”—dose matters for risk/benefit.

Step 3 — Special context: dose-related atrial fibrillation signal

Evidence from meta-analyses and regulatory communications indicates a dose-dependent increased risk of atrial fibrillation (AF) with higher-dose omega-3 products in certain higher-risk populations, particularly at 4 g/dayprescription-strength dosing. 

This does not mean dietary fish is dangerous; it means mega-dosing supplements should be intentional and medically supervised.

Root causes: why omega-3 runs low

1. Low fatty fish intake (most common) 

2. Relying only on ALA sources (flax/chia/walnuts) — conversion to EPA/DHA is limited 

3. Inconsistent supplementation (omega-3 status reflects consistency over time)

What to do next: a practical action plan

Tier 1 — Food sources + best practices (2–8 weeks)

AHA-style dietary baseline: aim for two servings of fish per week, especially fatty fish. 

High-yield EPA/DHA foods

• salmon, sardines, herring, trout, mackerel (note mercury guidance varies by species and region)

• oysters and some shellfish can contribute EPA/DHA

Best practices

• Prefer “repeatable defaults”: e.g., salmon bowl weekly + sardines twice weekly.

• If you don’t eat fish: use algae oil (often DHA-dominant; some products include EPA). 

Tier 2 — Supplementation (when appropriate)

Supplements can be useful when:

• you don’t eat fish regularly

• you have a clear biomarker goal (e.g., low omega-3 index) and want predictable improvement

• you need DHA support in pregnancy/lactation (see below)

Quality checklist

• Choose products with clear EPA and DHA amounts per serving (not just “fish oil 1000 mg”)

• Consider third-party testing (IFOS/USP/NSF are commonly used standards in the market—choose what aligns with your region)

Tier 3 — Clinical dosing (triglycerides / high-risk contexts)

For very high triglycerides, high-dose prescription omega-3 (often 4 g/day) is an evidence-backed therapeutic approach and should be managed by a clinician. 

Special populations

Pregnancy & lactation

European sources commonly cite pregnancy/lactation targets that include at least ~200 mg DHA/day (and/or an additional 100–200 mg DHA depending on baseline). 

Practical approach: 1–2 low-mercury fatty fish meals/week + targeted DHA if needed.

Safety notes (simple, practical)

• EFSA has stated that supplemental intakes of EPA+DHA up to 5 g/day do not raise safety concerns for adults (general safety framing; individual context still matters). 

• Higher doses (especially prescription-level) are where AF risk discussions appear in some populations. 

• If you take anticoagulants/antiplatelets, have arrhythmia history, or are planning high-dose omega-3, discuss with a clinician.

Complementary biomarkers to check: the “Omega-3 cluster”

If you’re optimizing EPA/DHA for outcomes (not just “a number”), pair it with:

1. Triglycerides, HDL, LDL (lipid context) 

2. hs-CRP (inflammation context; non-specific but useful)

3. ApoB / non-HDL-C (atherogenic burden context)

4. If available: an RBC-based omega-3 measure (Omega-3 Index) for longer-term status 

FAQ

Is the Omega-3 Index better than “fish oil dose”?

Often, yes—because it reflects what actually got into your cells, not what you swallowed. 

Is plant omega-3 (ALA) enough?

ALA is beneficial, but conversion to EPA/DHA is limited; EPA/DHA usually require fish/algae or supplements. 

Should I take omega-3 supplements every day?

Only if it supports a goal (low intake, low status, or clinician-directed therapy). For general health, many heart-health sources emphasize fish twice weekly as a baseline. 

Can omega-3 be “too high”?

High-dose omega-3 products (especially 4 g/day prescription forms) have shown a dose-related AF signal in some higher-risk groups, so dosing should be intentional. 

References

1) NIH Office of Dietary Supplements (ODS) — Omega-3 Fatty Acids: Health Professional Fact Sheet
https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/

2) American Heart Association — “Are you getting enough omega-3 fatty acids?” (fish twice weekly)
https://www.heart.org/en/news/2023/06/30/are-you-getting-enough-omega-3-fatty-acids

3) Mayo Clinic (2026) — Omega-3 in fish: How eating fish helps your heart (AHA fish recommendation referenced)
https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/omega-3/art-20045614

4) EFSA (2010) — Dietary Reference Values for fats: AI includes 250 mg/day EPA+DHA for adults; pregnancy/lactation DHA guidance (PDF)
https://www.nutritiondusport.fr/wp-content/uploads/2013/09/efsa-journal-2010-1461-acid-gras.pdf

5) European Commission Knowledge4Policy — Summary table referencing EFSA: 250 mg/day EPA+DHA adults; pregnancy/lactation minimum with DHA component
https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/dietary-fats-table-4_en

6) EFSA press release — Safety: supplemental EPA+DHA up to 5 g/day without safety concerns in adults
https://www.efsa.europa.eu/en/press/news/120727

7) NCCIH (NIH) — Omega-3 Supplements: What you need to know (fish oil vs algae oil; cod liver oil notes)
https://www.nccih.nih.gov/health/omega3-supplements-what-you-need-to-know

8) Schuchardt JP, et al. (2024) — Omega-3 world map update; Omega-3 Index definition (EPA+DHA % in RBC)
https://www.sciencedirect.com/science/article/pii/S0163782724000195

9) von Schacky C. (2014) — Omega-3 Index and cardiovascular health (review)
https://www.mdpi.com/2072-6643/6/2/799

10) EMA DHPC (2023) — Omega-3-acid ethyl ester medicines: dose-dependent increased AF risk (highest at 4 g/day)
https://www.ema.europa.eu/system/files/documents/dhpc/direct-healthcare-professional-communication-dhpc-omega-3-acid-ethyl-ester-medicines-dose-dependent_en.pdf

11) Huh JH, et al. (2022) — Review on omega-3 fatty acids and atrial fibrillation; dose-related signal in meta-analyses (PMC)
https://pmc.ncbi.nlm.nih.gov/articles/PMC10175873/

12) AHA news release (2019) — Prescription omega-3 medications work for high triglycerides; 4 g/day dosing concept
https://www.heart.org/en/news/2019/08/19/prescription-omega3-medications-work-for-high-triglycerides-advisory-says

13) PubMed — AHA Science Advisory (2019): Omega-3 fatty acids for management of hypertriglyceridemia
https://pubmed.ncbi.nlm.nih.gov/31422671/